2023-506564-14-00
已完成
1 期
A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.
Celgene International II S.a.r.l.19 个研究点 分布在 4 个国家目标入组 112 人开始时间: 2023年10月6日最近更新:
概览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Celgene International II S.a.r.l.
- 入组人数
- 112
- 试验地点
- 19
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
GSM-CT
Scientific
Celgene International II S.a.r.l.
研究点 (19)
Loading locations...
相似试验
尚未招募
1 期
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64
进行中（未招募）
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer2023-506700-12-00Genentech Inc.45
进行中（未招募）
1 期
A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers2024-515254-24-00Janssen Cilag International74
尚未招募
1 期
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.2025-523146-27-00Innovative Molecules GmbH30
撤回
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a pDNA Vaccine Candidate Against COVID-19 in Healthy Adults2023-505135-12-00Imam Abdulrahman Bin Faisal University60